Artiva Biotherapeutics’ (ARTV) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Artiva Biotherapeutics (NASDAQ:ARTV) in a research report sent to investors on Tuesday,Benzinga reports. They currently have a $23.00 target price on the stock.

Separately, HC Wainwright initiated coverage on shares of Artiva Biotherapeutics in a research report on Monday, December 30th. They set a “buy” rating and a $20.00 target price for the company. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $20.40.

Artiva Biotherapeutics Stock Performance

Shares of ARTV stock opened at $3.54 on Tuesday. The business has a fifty day moving average of $4.78 and a 200 day moving average of $9.29. Artiva Biotherapeutics has a 1 year low of $3.37 and a 1 year high of $17.31.

Institutional Investors Weigh In On Artiva Biotherapeutics

A number of institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets purchased a new position in Artiva Biotherapeutics during the third quarter worth approximately $42,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Artiva Biotherapeutics during the 4th quarter valued at approximately $52,000. Wells Fargo & Company MN raised its position in shares of Artiva Biotherapeutics by 64.0% during the 4th quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock worth $87,000 after purchasing an additional 3,361 shares during the last quarter. MetLife Investment Management LLC purchased a new position in Artiva Biotherapeutics in the 3rd quarter valued at about $135,000. Finally, JPMorgan Chase & Co. acquired a new stake in Artiva Biotherapeutics in the 3rd quarter worth about $166,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.